Characterization of BI 6727, a novel Polo-like kinase inhibitor with a distinct pharmacokinetic profile and efficacy in a model of taxane-resistant colon cancer

被引：0
|
作者：
Blagden, S. [1 ]
Olmos, D. [2 ]
Sharma, R. [1 ]
Barruiso, J. [2 ]
Medani, H. [1 ]
Versola, M. [3 ]
Murray, S. [3 ]
Smith, D. A. [3 ]
Dar, M. M. [3 ]
deBono, J. S. [2 ]
机构：
[1] Univ London Imperial Coll Sci Technol & Med, Dept Oncol, London, England
[2] Royal Marsden Hosp, Drug Dev Unit, Sutton, Surrey, England
[3] GlaxoSmithKline Inc, Res & Dev, Res Triangle Pk, NC USA
来源：
EJC SUPPLEMENTS | 2008年 / 6卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：135 / 135
页数：1
相关论文
共 45 条
  • [1] BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity
    Rudolph, Dorothea
    Steegmaier, Martin
    Hoffmann, Matthias
    Grauert, Matthias
    Baum, Anke
    Quant, Jens
    Haslinger, Christian
    Garin-Chesa, Pilar
    Adolf, Guenter R.
    CLINICAL CANCER RESEARCH, 2009, 15 (09) : 3094 - 3102
  • [2] BI6727, a polo-like kinase 1 inhibitor with promising efficacy on Burkitt lymphoma cells
    Chen, Er
    Pei, Renzhi
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2020, 48 (05)
  • [3] Pediatric Preclinical Testing Program (PPTP) evaluation of volasertib (BI 6727), a Polo-like kinase (PLK) inhibitor
    Smith, Malcolm
    Keir, Stephen
    Maris, John
    Kolb, Anders
    Reynolds, Patrick
    Kang, Min
    Carol, Hernan
    Lock, Richard
    Gorlick, Richard
    Kurmasheva, Raushan
    Billups, Catherine
    Houghton, Peter
    CANCER RESEARCH, 2012, 72
  • [4] Combination of Radiation and Polo-like Kinase 1 Inhibition with BI 6727 in Tumor Model A431
    Krause, M.
    Eicheler, W.
    Kummer, B.
    Doerfler, A.
    Yaromina, A.
    Baumann, M.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2011, 187 : 53 - 53
  • [5] Initial Testing (Stage 1) of the Polo-Like Kinase Inhibitor Volasertib (BI 6727), by the Pediatric Preclinical Testing Program
    Gorlick, Richard
    Kolb, E. Anders
    Keir, Stephen T.
    Maris, John M.
    Reynolds, C. Patrick
    Kang, Min H.
    Carol, Hernan
    Lock, Richard
    Billups, Catherine A.
    Kurmasheva, Raushan T.
    Houghton, Peter J.
    Smith, Malcolm A.
    PEDIATRIC BLOOD & CANCER, 2014, 61 (01) : 158 - 164
  • [6] A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours
    Schoffski, Patrick
    Awada, Ahmad
    Dumez, Herlinde
    Gil, Thierry
    Bartholomeus, Sylvie
    Wolter, Pascal
    Taton, Martine
    Fritsch, Holger
    Glomb, Patricia
    Munzert, Gerd
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (02) : 179 - 186
  • [7] Polo-like kinase 1 inhibitor BI 6727 induces DNA damage and exerts strong antitumor activity in small cell lung cancer
    Wang, Yuehong
    Wu, Linying
    Yao, Yinan
    Lu, Guohua
    Xu, Liming
    Zhou, Jianying
    CANCER LETTERS, 2018, 436 : 1 - 9
  • [8] A Phase I single dose escalation study of the novel Polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumours
    Schoeffski, P.
    Awada, A.
    Dumez, H.
    Gil, T.
    Bartholomeus, S.
    Selleslach, J.
    Taton, M.
    Fritsch, H.
    Peter, N.
    Munzert, G.
    EJC SUPPLEMENTS, 2008, 6 (12): : 14 - 15
  • [9] Polo-like kinase 1 inhibitor BI6727 sensitizes 9L gliosarcoma cells to ionizing irradiation
    Li, Nan
    Engels, Elette
    Davis, Jeremy A.
    Dipuglia, Andrew
    Vogel, Sarah
    Valceski, Michael
    Rosenfeld, Anatoly B.
    Lerch, Michael L. F.
    Corde, Stephanie
    Tehei, Moeava
    BIOMEDICAL PHYSICS & ENGINEERING EXPRESS, 2019, 5 (06):
  • [10] A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
    Lin, C-C
    Su, W-C
    Yen, C-J
    Hsu, C-H
    Su, W-P
    Yeh, K-H
    Lu, Y-S
    Cheng, A-L
    Huang, D. C-L
    Fritsch, H.
    Voss, F.
    Taube, T.
    Yang, J. C-H
    BRITISH JOURNAL OF CANCER, 2014, 110 (10) : 2434 - 2440
12345